Analysts Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Target Price at $45.90

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $46.7273.

A number of equities analysts recently issued reports on NAMS shares. Stifel Nicolaus upped their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners reaffirmed an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday. Needham & Company LLC upped their price target on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, HC Wainwright initiated coverage on NewAmsterdam Pharma in a report on Monday, October 20th. They set a “buy” rating and a $52.00 price objective on the stock.

NewAmsterdam Pharma Stock Up 4.2%

Shares of NAMS stock opened at $35.45 on Monday. The business has a fifty day simple moving average of $36.86 and a 200 day simple moving average of $29.84. The company has a market cap of $4.02 billion, a P/E ratio of -17.29 and a beta of 0.07. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. As a group, equities research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In related news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the transaction, the insider owned 73,481 shares in the company, valued at $2,443,243.25. This trade represents a 7.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75. Following the sale, the chief accounting officer owned 12,353 shares in the company, valued at approximately $410,737.25. This represents a 17.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 153,647 shares of company stock worth $5,484,253 over the last three months. Insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC Bancorp USA Inc. bought a new stake in NewAmsterdam Pharma in the third quarter valued at approximately $886,000. Polar Capital Holdings Plc lifted its position in shares of NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after purchasing an additional 393,855 shares during the period. HighVista Strategies LLC lifted its position in shares of NewAmsterdam Pharma by 65.1% in the 3rd quarter. HighVista Strategies LLC now owns 31,831 shares of the company’s stock worth $905,000 after purchasing an additional 12,557 shares during the period. Fred Alger Management LLC increased its position in shares of NewAmsterdam Pharma by 87.2% during the third quarter. Fred Alger Management LLC now owns 41,264 shares of the company’s stock worth $1,174,000 after buying an additional 19,227 shares during the period. Finally, Duquesne Family Office LLC increased its position in shares of NewAmsterdam Pharma by 131.2% during the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after buying an additional 1,091,525 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.